Sars-cov-2 vaccines
US-2024408193-A1 · Dec 12, 2024 · US
Cross-protective arenavirus vaccines and their method of use
US9446114B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9446114-B2 |
| Application number | US-201214232110-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 11, 2012 |
| Priority date | Jul 11, 2011 |
| Publication date | Sep 20, 2016 |
| Grant date | Sep 20, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to DNA vaccines that target multiple arenavirus agents singly or simultaneously.
First claim
Opening claim text (preview).
The invention claimed is: 1. A DNA vaccine comprising a nucleotide coding sequence that encodes one or more immunogenic proteins capable of generating a protective immune response against an arenavirus in a subject in need thereof, comprising: a coding sequence encoding a glycoprotein precursor of an arenavirus, optimized for said subject, wherein the coding sequence is SEQ ID NO: 1 or 2. 2. The DNA vaccine of claim 1 , wherein said coding sequence consists essentially of a coding sequence encoding a glycoprotein precursor domain of lassa virus (LASV-GPC). 3. The DNA vaccine of claim 1 , further comprising an adjuvant selected from the group consisting of interleukin-12, interleukin-15, interleukin-28 and RANTES (regulated on activation, normal T-cell expressed and secreted). 4. A method of inducing a protective immune response against an arenavirus comprising: administering a DNA vaccine of claim 1 or 2 to a subject in need thereof, and electroporating said subject. 5. The method of claim 4 , wherein the electroporating step comprises: delivering an electroporating pulse of energy to a site on said subject that administration step occurred. 6. The method of claim 5 , wherein the administrating step and electroporating step both occur in an intradermal layer of said subject. 7. The DNA vaccine of claim 1 or 2 , wherein said DNA vaccine consists essentially of one of said coding sequences. 8. The DNA vaccine of claim 1 or 2 , wherein said DNA vaccine consists essentially of at least two of said coding sequences.
Assignees
Inventors
Classifications
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
characterised by the route of administration · CPC title
DNA (RNA) vaccination · CPC title
- A61K39/12Primary
Viral antigens · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9446114B2 cover?
- The invention relates to DNA vaccines that target multiple arenavirus agents singly or simultaneously.
- Who is the assignee on this patent?
- Broderick Kate, Sardesai Niranjan, Cashman Kathleen, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).